Showing results (101-110 of 198) with videos related to

Sort By:
Pageof 20
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
Drug Safety|July 9, 2015
Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT StudyLinda de Jonge, Ester Garne, Rosa Gini, et al.
Ejhaem|July 18, 2022
An open-source, expert-designed decision tree application to support accurate diagnosis of myeloid malignanciesThomas Coats, Daniel Bean, Theodora Vatopoulou, et al.
British Journal of Haematology|February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patientsRory McCulloch, David Lewis, Nicola Crosbie, et al.
The Lancet. Oncology|February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trialMarek Trněný, Thierry Lamy, Jan Walewski, et al.
Prenatal Diagnosis|June 12, 2014
Prenatal diagnosis and epidemiology of multicystic kidney dysplasia in EuropeLouise Winding, Maria Loane, Diana Wellesley, et al.
Frontiers in Genetics|September 5, 2018
Across-Experiment Transcriptomics of Sheep Rumen Identifies Expression of Lipid/Oxo-Acid Metabolism and Muscle Cell Junction Genes Associated With Variation in Methane-Related PhenotypesRuidong Xiang, Jody McNally, Jude Bond, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
The Journal of Rheumatology|March 3, 2004
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTRJohn A Snowden, Jakob Passweg, John J Moore, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Pageof 20